380 results on '"de Vries, E. G. E"'
Search Results
2. 89Zr-trastuzumab PET supports clinical decision making in breast cancer patients, when HER2 status cannot be determined by standard work up
3. Web-based personalised information and support for patients with a neuroendocrine tumour: randomised controlled trial
4. Correction to: [89Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer
5. Reply to the letter to the editor ‘Toxicity adjustment in the ESMO-MCBS: a Gestalt approach?’ by Del Paggio
6. The antibody–drug conjugate target landscape across a broad range of tumour types
7. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)
8. ESMO-Magnitude of Clinical Benefit Scale version 1.1
9. ATR inhibition preferentially targets homologous recombination-deficient tumor cells
10. Microenvironment involved in FPR1 expression by human glioblastomas
11. Molecular imaging in ovarian cancer
12. Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial
13. Reply to the letter to the editor ‘The ESMO Magnitude of Clinical Benefit Scaling Tool: from theory to practice’ by Hartmann and the letter ‘Comment on ESMO Magnitude of Clinical Benefit Scale’ by Muhonen et al.
14. Long-term exposure to circulating platinum is associated with late effects of treatment in testicular cancer survivors
15. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)
16. Forced activation of Cdk1 via wee1 inhibition impairs homologous recombination
17. Heterogeneity in simvastatin-induced cytotoxicity in AML is caused by differences in Ras-isoprenylation
18. A bioinformatical and functional approach to identify novel strategies for chemoprevention of colorectal cancer
19. Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysis
20. Factors influencing catheter-related infections in the Dutch multicenter study on high-dose chemotherapy followed by peripheral SCT in high-risk breast cancer patients
21. Genetic factors influencing Pyrimidine-antagonist chemotherapy
22. Development of an optimal sampling strategy for clinical pharmacokinetic studies of the novel anthracycline disaccharide analogue MEN-10755
23. Neuropsychological investigation into the carcinoid syndrome
24. Expression of apoptosis-related proteins and morphological changes in a rat tumor model of human small cell lung cancer prior to and after treatment with radiotherapy, carboplatin, or combined treatment
25. Visualization of multidrug resistance in vivo
26. Longitudinal changes in cardiac function after cisplatin-based chemotherapy for testicular cancer
27. An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients
28. Deficiencies in fat-soluble vitamins in long-term users of somatostatin analogue
29. Molecular profile of ductal carcinoma in situ of the breast in BRCA1 and BRCA2 germline mutation carriers
30. Approaches to lung cancer treatment using the CD3E×GP-2-directed Bispecific Monoclonal Antibody BIS-1
31. Phase II study of intensive chemotherapy with autologous bone marrow transplantation in patients in complete remission of disseminated breast cancer
32. A case of localized Castleman's disease with systemic involvement: treatment and pathogenetic aspects
33. Identification of mismatch repair gene mutations in young patients with colorectal cancer and in patients with multiple tumours associated with hereditary non-polyposis colorectal cancer
34. Long-term cardiac follow-up in survivors of a malignant bone tumour
35. Efficacy of high-dose alkylating chemotherapy in HER2/neu-negative breast cancer
36. Abstracts of papers and posters
37. Abstracts of papers and posters Clinical Pharmacological Meeting
38. Local antitumour treatment in carcinoma patients with bispecific-monoclonal-antibody-redirected T cells
39. Analysis of the entire HLA region in susceptibility for cervical cancer: a comprehensive study
40. Soluble TRAIL concentrations are raised in patients with systemic lupus erythematosus
41. Plasma pharmacokinetics of uracil after an oral uracil challenge dose for dihydropyrimidine dehydrogenase (DPD) phenotyping
42. the potential of combinational regimen with non-steroidal anti-inflammatory drugs in the chemoprevention of colorectal cancer
43. Portal and Systemic Serum Growth Factor and Acute-Phase Response after Laparotomy or Partial Hepatectomy in Patients with Colorectal Liver Metastases: A Prognostic Role for C-reactive Protein and Hepatocyte Growth Factor
44. Continuously infused carboplatin used as radiosensitizer in locally unresectable non-small-cell lung cancer: a multicenter phase III study
45. Assessment of apoptosis by M30 immunoreactivity and the correlation with morphological criteria in normal colorectal mucosa, adenomas and carcinomas
46. Scientific Proceedings Second International Symposium on Cytostatic Drug Resistance
47. Detection of telomerase, its components, and human papillomavirus in cervical scrapings as a tool for triage in women with cervical dysplasia
48. Dysplasia in Fundic Gland Polyps is Associated with Nuclear β-Catenin Expression and Relatively High Cell Turnover Rates
49. Third International Symposium for health professionals in rheumatology: Enschede 6–9 June 1990
50. Topoisomerases, New Targets in Cancer Chemotherapy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.